DYNE THERAPEUTICS INC

Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

16 май 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

02 май 2022 15:05:01 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

10 мар 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

03 мар 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

18 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 янв 2022 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

02 дек 2021 07:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

04 ноя 2021 06:30:01 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

13 окт 2021 06:45:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

01 окт 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

28 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

27 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

20 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

05 авг 2021 06:30:01 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

25 июн 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Chief Scientific Officer Transition

02 июн 2021 15:05:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference

26 май 2021 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA

14 май 2021 06:00:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

06 май 2021 06:29:00 Источник Nasdaq GlobeNewswire

New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting

27 апр 2021 15:35:00 Источник Nasdaq GlobeNewswire